Unmet Needs in hATTR Amyloidosis in Europe | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Patient Education

Unmet Needs in hATTR Amyloidosis in Europe

key information

source: Global Alliance for Patient Access

year: 2021

summary/abstract:

People living with rare diseases face a unique set of challenges, from reaching a timely and accurate diagnosis to accessing treatment. Although individual rare diseases may impact only a small population, there are about 30 million people living in Europe with one of 6,000 identified rare diseases.

One such rare disease is hereditary transthyretin (hATTR) amyloidosis. It is caused by a hereditary gene mutation that leads to a build-up of abnormal protein in different bodily organs. The disease causes debilitating cardiovascular, neurological, renal or other symptoms. As the disease progresses, patients can experience difficulty walking, fatigue, chest pain, and weakness and pain in their limbs, making it difficult to continue with their normal lives.

Due to the complex nature of hATTR amyloidosis, and the impact on different organs, reaching a diagnosis can be a complex process. When hATTR amyloidosis is diagnosed and treated in a timely manner, however, disease progression can be stopped, giving patients hope for a better quality of life.

read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2025 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close